$22.78
6.22% today
Nasdaq, Apr 04, 08:48 pm CET
ISIN
US6951271005
Symbol
PCRX

Pacira Pharmaceuticals, Inc. Stock price

$24.29
+1.33 5.79% 1M
+8.40 52.86% 6M
+5.45 28.93% YTD
-4.72 16.27% 1Y
-53.06 68.60% 3Y
-6.51 21.14% 5Y
-62.52 72.02% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.60 2.41%
ISIN
US6951271005
Symbol
PCRX
Sector
Industry

Key metrics

Market capitalization $1.12b
Enterprise Value $1.28b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 7.15
EV/Sales (TTM) EV/Sales 1.82
P/S ratio (TTM) P/S ratio 1.60
P/B ratio (TTM) P/B ratio 1.44
Revenue growth (TTM) Revenue growth 3.85%
Revenue (TTM) Revenue $700.97m
EBIT (operating result TTM) EBIT $97.57m
Free Cash Flow (TTM) Free Cash Flow $178.75m
Cash position $484.62m
EPS (TTM) EPS $-2.20
P/E forward 18.37
P/S forward 1.49
EV/Sales forward 1.70
Short interest 18.64%
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

3x Buy
43%
3x Hold
43%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
43%
Hold
43%
Sell
14%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
701 701
4% 4%
100%
- Direct Costs 228 228
6% 6%
32%
473 473
9% 9%
68%
- Selling and Administrative Expenses 215 215
11% 11%
31%
- Research and Development Expense 82 82
7% 7%
12%
176 176
8% 8%
25%
- Depreciation and Amortization 79 79
4% 4%
11%
EBIT (Operating Income) EBIT 98 98
12% 12%
14%
Net Profit -100 -100
337% 337%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- -- Initial topline results from two-part, randomized, double-blind, active-controlled study expected late 2026 -- BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovat...
Neutral
GlobeNewsWire
3 days ago
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025.
Positive
Seeking Alpha
21 days ago
Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pa...
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 790
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today